You are about to leave Risk Strategies website and view the content of an external website.
You are leaving risk-strategies.com
By accessing this link, you will be leaving Risk Strategies website and entering a website hosted by another party. Please be advised that you will no longer be subject to, or under the protection of, the privacy and security policies of Risk Strategies website. We encourage you to read and evaluate the privacy and security policies of the site you are entering, which may be different than those of Risk Strategies.
Risk Strategies Consulting’s fourth-quarter Clinical Rx Pipeline Report is now available. This edition provides updates on impactful drug approvals and a forward-looking analysis of the clinical biosimilar and cell & gene therapy pipelines. In addition, the report reviews multiple topics including:
As a full-service consultancy with on-staff clinicians and pharmacists for plan sponsors with mid-to-high aggregate drug spend, this knowledge is critical for managing costs and strategic planning. Our team of clinical experts is here to help.